Zynex PE Ratio 2010-2025 | ZYXI
Current and historical p/e ratio for Zynex (ZYXI) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Zynex PE ratio as of July 25, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Zynex PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2025-07-25 | 2.58 | 0.00 | |
2025-03-31 | 2.20 | $-0.24 | 0.00 |
2024-12-31 | 8.01 | $0.09 | 89.00 |
2024-09-30 | 8.16 | $0.15 | 54.40 |
2024-06-30 | 9.32 | $0.18 | 51.78 |
2024-03-31 | 12.37 | $0.23 | 53.78 |
2023-12-31 | 10.89 | $0.27 | 40.33 |
2023-09-30 | 8.00 | $0.43 | 18.60 |
2023-06-30 | 9.59 | $0.46 | 20.85 |
2023-03-31 | 12.00 | $0.45 | 26.67 |
2022-12-31 | 13.91 | $0.44 | 31.61 |
2022-09-30 | 9.07 | $0.47 | 19.30 |
2022-06-30 | 7.98 | $0.49 | 16.13 |
2022-03-31 | 6.23 | $0.49 | 12.78 |
2021-12-31 | 8.14 | $0.44 | 18.54 |
2021-09-30 | 9.30 | $0.25 | 36.53 |
2021-06-30 | 12.68 | $0.14 | 92.96 |
2021-03-31 | 12.47 | $0.15 | 85.69 |
2020-12-31 | 10.99 | $0.25 | 44.76 |
2020-09-30 | 14.25 | $0.28 | 50.56 |
2020-06-30 | 20.31 | $0.30 | 67.71 |
2020-03-31 | 9.04 | $0.27 | 33.16 |
2019-12-31 | 6.43 | $0.25 | 25.26 |
2019-09-30 | 7.76 | $0.25 | 31.65 |
2019-06-30 | 7.34 | $0.26 | 27.86 |
2019-03-31 | 3.67 | $0.27 | 13.48 |
2018-12-31 | 2.40 | $0.26 | 9.11 |
2018-09-30 | 2.36 | $0.28 | 8.39 |
2018-06-30 | 2.46 | $0.27 | 9.02 |
2018-03-31 | 2.69 | $0.25 | 10.56 |
2017-12-31 | 2.52 | $0.21 | 12.06 |
2017-09-30 | 1.47 | $0.12 | 12.41 |
2017-06-30 | 0.48 | $0.07 | 6.53 |
2017-03-31 | 0.24 | $0.02 | 13.42 |
2016-12-31 | 0.24 | 0 | 0.00 |
2016-09-30 | 0.25 | $-0.04 | 0.00 |
2016-06-30 | 0.19 | $-0.06 | 0.00 |
2016-03-31 | 0.27 | $-0.07 | 0.00 |
2015-12-31 | 0.36 | $-0.09 | 0.00 |
2015-09-30 | 0.14 | $-0.04 | 0.00 |
2015-06-30 | 0.16 | $-0.02 | 0.00 |
2015-03-31 | 0.11 | $-0.16 | 0.00 |
2014-12-31 | 0.13 | $-0.18 | 0.00 |
2014-09-30 | 0.12 | $-0.34 | 0.00 |
2014-06-30 | 0.23 | $-0.36 | 0.00 |
2014-03-31 | 0.18 | $-0.25 | 0.00 |
2013-12-31 | 0.15 | $-0.22 | 0.00 |
2013-09-30 | 0.11 | $-0.07 | 0.00 |
2013-06-30 | 0.20 | $-0.05 | 0.00 |
2013-03-31 | 0.24 | $0.03 | 8.97 |
2012-12-31 | 0.29 | $0.05 | 6.27 |
2012-09-30 | 0.33 | $0.05 | 5.98 |
2012-06-30 | 0.34 | $0.06 | 5.31 |
2012-03-31 | 0.33 | $0.06 | 5.12 |
2011-12-31 | 0.28 | $0.05 | 5.08 |
2011-09-30 | 0.32 | $0.04 | 8.86 |
2011-06-30 | 0.36 | $0.03 | 13.00 |
2011-03-31 | 0.29 | $0.01 | 0.00 |
2010-12-31 | 0.24 | $0.01 | 0.00 |
2010-09-30 | 0.21 | $0.02 | 11.43 |
2010-06-30 | 0.24 | $0.03 | 8.67 |
2010-03-31 | 0.37 | $0.05 | 8.16 |
2009-12-31 | 0.43 | $0.07 | 5.94 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Products Manufacturing | $0.078B | $0.192B |
Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Abbott Laboratories (ABT) | United States | $220.159B | 25.82 |
Boston Scientific (BSX) | United States | $157.028B | 37.51 |
Stryker (SYK) | United States | $154.023B | 32.21 |
EssilorLuxottica (ESLOY) | France | $136.572B | 0.00 |
Medtronic (MDT) | Ireland | $119.200B | 16.90 |
Lonza Group Ag (LZAGY) | Switzerland | $50.282B | 0.00 |
Haleon (HLN) | United Kingdom | $44.384B | 25.33 |
ResMed (RMD) | United States | $40.346B | 30.30 |
GE HealthCare Technologies (GEHC) | United States | $35.536B | 16.87 |
Agilent Technologies (A) | United States | $34.139B | 22.26 |
Terumo (TRUMY) | Japan | $25.843B | 33.57 |
Koninklijke Philips (PHG) | Netherlands | $25.190B | 17.68 |
Insulet (PODD) | United States | $20.424B | 80.17 |
Zimmer Biomet Holdings (ZBH) | United States | $19.300B | 12.40 |
Baxter (BAX) | United States | $14.995B | 11.20 |
Smith & Nephew SNATS (SNN) | United Kingdom | $13.871B | 0.00 |
Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
Demant (WILYY) | Denmark | $8.633B | 0.00 |
Bio-Rad Laboratories (BIO) | United States | $7.189B | 25.02 |
Lantheus Holdings (LNTH) | United States | $5.046B | 12.73 |
Perrigo (PRGO) | Ireland | $3.908B | 9.91 |
Prestige Consumer Healthcare (PBH) | United States | $3.799B | 16.97 |
Haemonetics (HAE) | United States | $3.613B | 16.46 |
Envista Holdings (NVST) | United States | $3.525B | 29.30 |
Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
ICU Medical (ICUI) | United States | $3.197B | 23.58 |
LeMaitre Vascular (LMAT) | United States | $1.862B | 41.63 |
QuidelOrtho (QDEL) | United States | $1.852B | 12.74 |
AtriCure (ATRC) | United States | $1.559B | 0.00 |
Acuren (TIC) | United States | $1.441B | 0.00 |
Green Thumb Industries (GTBIF) | United States | $1.332B | 29.95 |
AdaptHealth (AHCO) | United States | $1.274B | 12.93 |
Phibro Animal Health (PAHC) | United States | $1.183B | 15.12 |
Neogen (NEOG) | United States | $1.133B | 14.50 |
BioLife Solutions (BLFS) | United States | $1.080B | 0.00 |
Curaleaf Holdings (CURLF) | Canada | $0.964B | 0.00 |
InMode (INMD) | Israel | $0.930B | 9.38 |
Kestra Medical Technologies (KMTS) | United States | $0.850B | 0.00 |
Tilray Brands (TLRY) | Canada | $0.693B | 0.00 |
Maravai LifeSciences Holdings (MRVI) | United States | $0.685B | 0.00 |
Valneva SE (VALN) | France | $0.654B | 0.00 |
Evolus (EOLS) | United States | $0.614B | 0.00 |
Owens & Minor (OMI) | United States | $0.609B | 5.05 |
CeriBell (CBLL) | United States | $0.547B | 0.00 |
ZimVie (ZIMV) | United States | $0.521B | 23.70 |
Surmodics (SRDX) | United States | $0.515B | 0.00 |
SNDL (SNDL) | Canada | $0.398B | 0.00 |
SEMPERIT AG HLD (SEIGY) | Austria | $0.359B | 0.00 |
Cresco Labs (CRLBF) | United States | $0.336B | 0.00 |
Sanuwave Health (SNWV) | United States | $0.324B | 0.00 |
VAREX IMAGING (VREX) | United States | $0.323B | 11.89 |
Capricor Therapeutics (CAPR) | United States | $0.322B | 0.00 |
Quanterix (QTRX) | United States | $0.292B | 0.00 |
Aurora Cannabis (ACB) | Canada | $0.272B | 80.67 |
Cerus (CERS) | United States | $0.266B | 0.00 |
OraSure Technologies (OSUR) | United States | $0.251B | 0.00 |
Viemed Healthcare (VMD) | United States | $0.242B | 20.40 |
Biote (BTMD) | United States | $0.236B | 6.65 |
Canopy Growth (CGC) | Canada | $0.234B | 0.00 |
Verano Holdings (VRNOF) | United States | $0.230B | 0.00 |
Sanara MedTech (SMTI) | United States | $0.227B | 0.00 |
Omeros (OMER) | United States | $0.224B | 0.00 |
Brainsway (BWAY) | Israel | $0.222B | 58.65 |
Organigram Global (OGI) | Canada | $0.205B | 0.00 |
Utah Medical Products (UTMD) | United States | $0.190B | 15.65 |
High Tide (HITI) | Canada | $0.188B | 0.00 |
TriSalus Life Sciences (TLSI) | United States | $0.173B | 0.00 |
Vireo Growth (VREOF) | United States | $0.170B | 0.00 |
Exagen (XGN) | United States | $0.155B | 0.00 |
TerrAscend (TSNDF) | Canada | $0.135B | 0.00 |
FitLife Brands (FTLF) | United States | $0.121B | 14.91 |
MacroGenics (MGNX) | United States | $0.108B | 0.00 |
Jin Medical (ZJYL) | China | $0.102B | 0.00 |
Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
Fonar (FONR) | United States | $0.100B | 12.86 |
Quipt Home Medical (QIPT) | United States | $0.097B | 0.00 |
Apyx Medical (APYX) | United States | $0.096B | 0.00 |
Safety Shot (SHOT) | United States | $0.090B | 0.00 |
Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
Veru (VERU) | United States | $0.082B | 0.00 |
Agape ATP (ATPC) | $0.066B | 0.00 | |
ImmuCell (ICCC) | United States | $0.060B | 0.00 |
Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
Modular Medical (MODD) | United States | $0.039B | 0.00 |
United-Guardian (UG) | United States | $0.038B | 13.29 |
Nephros (NEPH) | United States | $0.038B | 51.00 |
Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
INLIF (INLF) | $0.016B | 0.00 | |
Flora Growth (FLGC) | United States | $0.014B | 0.00 |
Senestech (SNES) | United States | $0.013B | 0.00 |
Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
Sharps Technology (STSS) | United States | $0.006B | 0.00 |
GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
Akanda (AKAN) | Canada | $0.002B | 0.00 |
InterCure (INCR) | Israel | $0.000B | 0.00 |
InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |